Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study

Abstract

Our results suggest that some patients can benefit from Ed without an accompanying immunomodulatory agent and that efficacy can be achieved with the addition of lenalidomide at the time of progression. No new safety signals were detected, except for thrombocytopenia in 1 patient on Ed.